47 results
425
SLRN
Acelyrin, Inc.
6 Feb 25
Business combination disclosure
7:47pm
Section 16(b)
Stockholder Litigation
Certain Tax Matters
Post-Closing Board of Directors
Termination of Company Plans
Employee Matters
ARTICLE VI …
Tax Representation Letters
-iii-
AGREEMENT AND PLAN OF MERGER
This AGREEMENT AND PLAN OF MERGER (this “Agreement”), dated as of February 6, 2025
425
EX-2.1
SLRN
Acelyrin, Inc.
6 Feb 25
Business combination disclosure
5:21pm
Litigation
Certain Tax Matters
Post-Closing Board of Directors
Termination of Company Plans
Employee Matters
ARTICLE VI CONDITIONS
Conditions to Each …
Interpretation; Construction
Certain Definitions
Exhibit A
Certificate of Incorporation of the Surviving Corporation
Exhibit B
Tax Representation Letters
425
EX-99.4
SLRN
Acelyrin, Inc.
6 Feb 25
Business combination disclosure
5:21pm
Company RSUs or Company PSUs settled in Subject Securities (to pay any Tax withholding obligations) or (B) transfers for receipt upon settlement
8-K
EX-2.1
SLRN
Acelyrin, Inc.
6 Feb 25
Entry into a Material Definitive Agreement
5:19pm
’ Insurance
Takeover Statutes
Section 16(b)
Stockholder Litigation
Certain Tax Matters
Post-Closing Board of Directors
Termination of Company Plans
Employee … of the Surviving Corporation
Exhibit B
Tax Representation Letters
-iii-
AGREEMENT AND PLAN OF MERGER
This AGREEMENT AND PLAN OF MERGER (this “Agreement”), dated
8-K
EX-99.3
SLRN
Acelyrin, Inc.
6 Feb 25
Entry into a Material Definitive Agreement
5:19pm
of such Securityholder’s Company RSUs or Company PSUs settled in Subject Securities (to pay any Tax withholding obligations) or (B) transfers for receipt
8-K
EX-10.1
k0bee8mb bke2x5tabx
10 Dec 24
ACELYRIN, INC. Announces Topline Results From Phase 2b/3 Study of Izokibep for the Treatment of Uveitis
4:34pm
S-3
EX-1.2
wd6fex0zzj
13 Nov 24
Shelf registration
5:26pm
S-3
EX-4.6
ghysbt0r
13 Nov 24
Shelf registration
5:26pm
S-3
EX-4.8
j5sh8vh3cauje48
13 Nov 24
Shelf registration
5:26pm
S-3
EX-4.9
nfbgu
13 Nov 24
Shelf registration
5:26pm
S-3
EX-4.10
6gyq9o
13 Nov 24
Shelf registration
5:26pm
S-3
h046htk9l80i3
13 Nov 24
Shelf registration
5:26pm
8-K
EX-99.1
x0cmmlhqm
13 Nov 24
Independent Auditor’s Report
4:21pm
8-K
EX-10.1
2aae3vk8
13 Aug 24
Focuses Strategy on Lonigutamab and Reports Second Quarter 2024 Financial Results
4:14pm
8-K
EX-10.1
v5xptx
9 May 24
ACELYRIN, INC. Provides Business Update and Highlights Key Upcoming Milestones
8:13am
8-K
EX-10.2
78luqbgfaayv
9 May 24
ACELYRIN, INC. Provides Business Update and Highlights Key Upcoming Milestones
8:13am
DEF 14A
19o ie7e5np
22 Apr 24
Definitive proxy
4:10pm